EMA is examining approval of Merck's corona drug

The European Medicines Agency EMA is now examining the approval of a corona drug from Merck.

Amsterdam - So far, it looks rather poor with drugs against Corona.

The one remedy against Sars-CoV2 is still missing.

The US company Merck recently made headlines with the pill Molnupiravir.

The drug was originally developed for the flu.

But initial studies have shown that very difficult courses can be prevented with it.

EMA is reviewing approval of Merck's corona pill molnupiravir

According to its own information, the EMA is now examining approval of the corona pill.

Initial studies suggest that the drug has the ability to reduce the build-up of Sars-CoV-2 in the body, thereby preventing hospitalization or the death of a Covid-19 patient, according to an EMA press release.

The EMA will now assess the effectiveness, safety and quality of molnupiravir according to the usual EU standards.

As the EMA announced on Monday, the EMA's Committee for Medicinal Products for Human Use (CHMP) initiated an ongoing review process for the drug molnupiravir for the treatment of adult Covid-19 patients.